LENZ Therapeutics LENZ Insider Ownership

NASDAQ LENZ

$3.22 +0.03 (+0.94%)

As of: Oct 21, 2026 · 3:59 PM EDT

Insider Holdings by Owner

3.76Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

9.98%

■0% pp QoQ

Shares Held by Insiders

3.13Mn

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

31.42Mn

31,416,892 shares

Direct Holdings

1.18Mn

Indirect: 1.96Mn

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the trailing 12 months, LENZ insiders bought $654,871 worth of shares (53.88K shares) and sold $261,022 worth (10K shares) in open-market trades.

Behind LENZ Therapeutics' open-market trades in the past 12 months were 4 insiders buying and one insider selling.
Among LENZ Therapeutics insiders, Evert B. Schimmelpennink (President, CEO and Secretary) led open-market buying over the past 12 months with $251,411 of purchases (28.09K shares); the latest was on March 27, 2026.
On the sell side, Shawn Olsson (Chief Commercial Officer) led open-market sales of LENZ Therapeutics stock over the past 12 months with $261,022 (10K shares), most recently on November 17, 2025.
In transactions other than open-market trades, LENZ Therapeutics insiders acquired 10K shares through option exercises and conversions over the past 12 months.
Per Business Quant, LENZ insiders together hold 3.13Mn shares based on their latest Form 4 filings, or 9.98% of the 31.42Mn shares outstanding; that total is unchanged from 3.13Mn shares at the end of Q2 2026 and up 1.75% from 3.08Mn shares at the end of Q3 2025.
Of the 3.13Mn shares held by LENZ Therapeutics insiders, 1.18Mn shares (37.52%) are held directly and 1.96Mn shares (62.48%) indirectly, through trusts, partnerships, family members and other entities.
Per Business Quant, 8 insiders of LENZ hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
LENZ Therapeutics' three biggest insider holders are Versant Venture Capital VI, L.P. (10% owner, 1.81Mn shares), James W. McCollum (Director, 631.1K shares) and Ra Capital Management, L.P. (Director and 10% owner, 573.45K shares), based on their latest Form 4 filings.
Versant Venture Capital VI, L.P. alone accounts for 57.90% of the shares held by LENZ Therapeutics insiders.
In the past year, 11 insiders of LENZ Therapeutics submitted 17 Form 4 filings reporting trades, awards or other transactions.
These insider figures for LENZ Therapeutics are based on Form 4 filings through June 15, 2026.

Form 4 Holdings

Insiders Holding LENZ

Insiders 10

Shares held 3.76Mn

Of outstanding 11.98%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Venture Capital Vi, L.P. Versant	TenPercentOwner	1,050,599	764,127	1,814,726	48.2%	02 Oct, 2025
2	Biocapital, L.P. Samsara	TenPercentOwner	0	1,208,498	1,208,498	32.1%	13 Apr, 2022
3	Capital Management, L.P. Ra	Director, TenPercentOwner	0	573,453	573,453	15.2%	25 Mar, 2024
4	Evert B. Schimmelpennink	President, Ceo And Secretary	77,289	0	77,289	2.1%	30 Mar, 2026
5	Phil Gutry	Chief Business Officer	42,850	0	42,850	1.1%	13 Apr, 2022
6	Marc Odrich	Chief Medical Officer	14,229	0	14,229	0.4%	25 Mar, 2024
7	Daniel R. Chevallard	Chief Financial Officer	12,886	0	12,886	0.3%	30 Mar, 2026
8	James W Mccollum	Director	10,500	0	10,500	0.3%	10 Nov, 2025
9	Jeffrey P. George	Director	5,592	0	5,592	0.1%	30 Mar, 2026
10	Shawn Olsson	Chief Commercial Officer	4,733	0	4,733	0.1%	19 Nov, 2025

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

172 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
15 Jun, 2026	Capital Management, L.P. Ra	Director, TenPercentOwner	Acquired A	22,100	$0.00	$0	22,100	Indirect
15 Jun, 2026	Kimberlee C Drapkin	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
15 Jun, 2026	Zachary Scheiner	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
15 Jun, 2026	James W Mccollum	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
15 Jun, 2026	Frederic Guerard	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
15 Jun, 2026	Jeffrey P. George	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
15 Jun, 2026	Shelley B Thunen	Director	Acquired A	22,100	$0.00	$0	22,100	Direct
27 Mar, 2026	Jeffrey P. George	Director	Acquired P	5,592	$8.92	$49.89K	5,592	Direct
27 Mar, 2026	Daniel R. Chevallard	Chief Financial Officer	Acquired P	7,500	$8.57	$64.28K	12,886	Direct
27 Mar, 2026	Evert B. Schimmelpennink	President, Ceo And Secretary	Acquired P	28,089	$8.95	$251.41K	77,289	Direct
02 Jan, 2026	Shawn Olsson	Chief Commercial Officer	Acquired A	84,200	$0.00	$0	84,200	Direct
02 Jan, 2026	Daniel R. Chevallard	Chief Financial Officer	Acquired A	84,200	$0.00	$0	84,200	Direct
02 Jan, 2026	Marc Odrich	Chief Medical Officer	Acquired A	84,200	$0.00	$0	84,200	Direct
02 Jan, 2026	Evert B. Schimmelpennink	President, Ceo And Secretary	Acquired A	358,100	$0.00	$0	358,100	Direct
02 Jan, 2026	Marc Odrich	Chief Medical Officer	Acquired A	14,000	$0.00	$0	14,000	Direct
02 Jan, 2026	Shawn Olsson	Chief Commercial Officer	Acquired A	14,000	$0.00	$0	14,000	Direct
02 Jan, 2026	Daniel R. Chevallard	Chief Financial Officer	Acquired A	14,000	$0.00	$0	14,000	Direct
17 Nov, 2025	Shawn Olsson	Chief Commercial Officer	Acquired M	10,000	$2.08	$20.80K	14,733	Direct
17 Nov, 2025	Shawn Olsson	Chief Commercial Officer	Disposed S	4,212	$25.74	$108.41K	10,521	Direct
17 Nov, 2025	Shawn Olsson	Chief Commercial Officer	Disposed S	5,788	$26.37	$152.61K	4,733	Direct

Showing 1 to 20 of 172 transactions